NASDAQ:CDMOAvid Bioservices Stock Price, Forecast & News

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CDMO shares have increased by 44.8% and is now trading at $6.53. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avid Bioservices.

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Avid Bioservices.

Avid Bioservices Inc (NASDAQ:CDMO) issued its earnings results on Tuesday, June, 30th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. The biopharmaceutical company earned $12.55 million during the quarter, compared to analysts' expectations of $9.55 million. Avid Bioservices had a negative return on equity of 22.29% and a negative net margin of 17.53%. View Avid Bioservices' earnings history.

Shares of Avid Bioservices reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

Avid Bioservices updated its FY 2021 After-Hours earnings guidance on Tuesday, June, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $76-81 million, compared to the consensus revenue estimate of $83.85 million.

4 equities research analysts have issued 12-month price objectives for Avid Bioservices' shares. Their forecasts range from $7.50 to $11.00. On average, they expect Avid Bioservices' stock price to reach $9.38 in the next year. This suggests a possible upside of 43.6% from the stock's current price. View analysts' price targets for Avid Bioservices.

Media coverage about CDMO stock has trended negative on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avid Bioservices earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Avid Bioservices.

Some companies that are related to Avid Bioservices include Cytokinetics (CYTK), MacroGenics (MGNX), Zogenix (ZGNX), BELLUS Health (BLUSF), Mersana Therapeutics (MRSN), Intercept Pharmaceuticals (ICPT), Revance Therapeutics (RVNC), ZEALAND PHARMA/S (ZEAL), Karyopharm Therapeutics (KPTI), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Esperion Therapeutics (ESPR), Innoviva (INVA), Kiniksa Pharmaceuticals (KNSA) and Heron Therapeutics (HRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Biopharma (ARRY), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Alibaba Group (BABA) and Crispr Therapeutics (CRSP).

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDMO stock can currently be purchased for approximately $6.53.

Avid Bioservices has a market capitalization of $369.01 million and generates $59.70 million in revenue each year. The biopharmaceutical company earns $-10,470,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Avid Bioservices employs 211 workers across the globe.

The official website for Avid Bioservices is www.avidbio.com.

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]